- Compound with AMPK agonistic activity and preparation and application of prodrug thereof
-
The invention relates to a compound with AMPK agonistic activity and a prodrug thereof, and as well as a preparation method and medical application of a prodrug thereof. The compound has the structure shown in the formula (I), and the prodrug of the compound has the structure shown in the formula (II), wherein each group and the substituent are as defined in the specification. The invention discloses a preparation method of the compound and application of the compound in prevention and treatment AMPK related diseases, and the AMPK related diseases include, but are not limited to, energy metabolism abnormality related diseases. Neurodegenerative diseases and inflammation-related diseases and the like.
- -
-
Paragraph 0598-0601
(2021/10/27)
-
- A 1 - chloroethyl cyclohexyl propyl ester preparation method
-
The invention relates to a preparation method of 1-chloroethyl cyclohexyl propyl carbonate and belongs to the field of chemicals. The preparation method of 1-chloroethyl cyclohexyl propyl carbonate comprises the following steps of: adding triethylamine or pyridine or N,N-dimethylaniline into trichloromethyl chloroformate at the temperature between 10 DEG C below zero and 0 DEG C, and dropwise adding paraldehyde to carry out reaction; adding triethylamine or pyridine or N,N-dimethylaniline after reaction, dropwise adding cyclohexanol under the condition that the temperature in a reactor is below 20 DEG C, and stirring to carry out reaction; taking a product of reaction, washing with water, and distilling by reducing pressure to obtain an organic phase which is 1-chloroethyl cyclohexyl propyl carbonate. The synthesized 1-chloroethyl cyclohexyl propyl carbonate is high in yield and purity and low in cost, and the preparation method of 1-chloroethyl cyclohexyl propyl carbonate is easy to control in the preparation process, is easy to operate, is low in risk and is particularly suitable for industrial production.
- -
-
Paragraph 0030-0033
(2017/05/27)
-
- Substituted aza indole compounds and salts thereof, composition and use thereof
-
The invention provides a substituted azaindole compound having a structure as represented by a formula (I) and a pharmaceutically acceptable salt and a medicinal preparation thereof. The compound is used for adjusting activity of protein kinase and adjusting intercellular or intracellular signal response. The invention further relates to a pharmaceutical composition including the compound and a method of applying the pharmaceutical composition to treatment of highly proliferative diseases of mammals, especially of mankind.
- -
-
Paragraph 0586; 0587; 0611; 0613; 0614
(2018/11/03)
-
- SUBSTITUTED AZAINDOLE COMPOUNDS, SALTS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF USE
-
The present invention provides substituted azaindole prodrugs, methods of making said prodrugs, pharmaceutical compositions of said prodrugs and methods of using said prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as cancer.
- -
-
Paragraph 0435-0436; 0453-0454
(2014/03/24)
-
- SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES
-
There are provided compounds of the formula wherein X, Y, Z, R1, R2, R3 and R4 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.
- -
-
Paragraph 0123
(2013/09/26)
-
- New CRTH2 Antagonists
-
The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.
- -
-
Page/Page column 66
(2012/12/13)
-
- PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE
-
The invention relates to prodrugs of fused heterocyclic inhibitors of D-amino oxidase (DAAO) and methods of treating diseases and conditions, wherein modulation of D-amino acid oxidase activity, D-serine levels, D-serine oxidative products and NMDA receptor activity in the nervous system of a mammalian subject is effective.
- -
-
Page/Page column 94; 95
(2011/02/26)
-
- GABA ANALOGS, COMPOSITIONS, AND METHODS FOR MANUFACTURING THEREOF
-
The invention provides novel compounds of Formula (I), pharmaceutical compositions and methods of synthesis thereof.
- -
-
Page/Page column 17-18
(2009/10/22)
-
- 2-ARYLMETHYLAZETIDINE-CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVE OR ITS SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
-
The present invention provides a 2-arylmethylazetidine-carbapenem-3-carboxylic acid ester derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The 2-arylmethylazetidine-carbapenem-3-carboxylic acid ester derivatives or their pharmaceutically acceptable salts show high oral absorption rate, and thus can be orally administered. The active metabolites thereof have a broad spectrum of antibacterial activities against Gram-positive and Gram-negative bacteria and excellent antibacterial activities against methicillin-resistant Staphylococcus aurus (MRSA) and quinolone-resistant strains (QRS). In particular, the acid addition salts of the 2-arylmethylazetidine-carbapenem-3-carboxylic acid ester derivatives are obtained in crystalline forms having excellent stability.
- -
-
Page/Page column 17-18
(2009/06/27)
-
- GABA ANALOGS, COMPOSITIONS AND METHODS FOR MANUFACTURING THEREOF
-
The invention provides novel compounds of Formula (I), pharmaceutical compositions and methods of synthesis thereof.
- -
-
Page/Page column 6-7
(2008/12/05)
-
- CaSR ANTAGONIST
-
The present invention provides a compound having a calcium-sensitive receptor antagonistic action, a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis. A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the description.
- -
-
Page/Page column 55
(2008/06/13)
-
- METHOD FOR PRODUCTION OF CANDESARTAN
-
The invention relates to novel methods for the production of Candesartan, or a protected form of Candesartan, a Candesartan salt or ester, compounds of application in said method, methods for production thereof, use thereof in said method, a novel polymorph of Candesartan cilexetil, a method for production and use thereof for production of a medicament.
- -
-
Page/Page column 24
(2010/11/08)
-
- PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS
-
The invention relates to new therapeutically useful pyridazin-3(2H)-one derivatives, to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent and selective inhibitors of phosphodiesterase 4 (PDE4) and are thus useful in the treatment, prevention and suppression of related pathological conditions, diseases and disorders, in particular asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, topic dermatitis, psoriasis or irritable bowel disease.
- -
-
Page/Page column 66
(2008/06/13)
-
- NOVEL PHENYLALANINE DERIVATIVE
-
The present invention relates to the following phenylalanine derivatives or analogues thereof having an antagonistic activity to α4 integrin and therapeutic agents for various diseases concerning α4 integrin.
- -
-
-
- CARBIDOPA PRODRUGS AND USES THEREOF
-
Prodrugs of carbidopa, derivatives of carbidopa prodrugs, methods of making prodrugs of carbidopa and derivatives thereof, methods of using prodrugs of carbidopa and derivatives thereof, and compositions of prodrugs of carbidopa and derivatives thereof are disclosed.
- -
-
-
- NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF
-
A benzophenone derivative represented by the following formula: whereinR1 represents, for example, an optionally substituted heterocyclic group, or a substituted phenyl group; Z represents, for example, an alkylene group; R2 represents, for example, a carboxyl group optionally protected with alkyl;R3 represents, for example, an optionally protected hydroxyl group; R4 represents, for example, an optionally substituted cycloalkyloxy group; and R5 represents, for example, a hydrogen atom, ???or a salt thereof has anti-arthritic activity, inhibits bone destruction caused by arthritis, and provides high safety and excellent pharmacokinetics and thus is useful as therapeutic agent for arthritis. These compounds have inhibitory effect on AP-1 activity and are useful as preventive or therapeutic agent for diseases in which excessive expression of AP-1 is involved.
- -
-
-
- Prodrugs of CL316243: A selective β3-adrenergic receptor agonist for treating obesity and diabetes
-
CL316243 is a highly selective and potent β3-adrenergic receptor agonist, and has been shown in rodent models to be an effective agent for treating obesity and Type II diabetes. To improve the oral absorption and pharmacokinetic profiles of CL316243, a number of prodrugs have been synthesized and evaluated. Several ester-type prodrugs show significant improvements in oral bioavailability in both rodent and primate models.
- Sum,Gilbert,Venkatesan,Lim,Wong,O'Dell,Francisco,Chen,Grosu,Baker,Ellingboe,Malamas,Gunawan,Primeau,Largis,Steiner
-
p. 1921 - 1926
(2007/10/03)
-
- 2-thiosubstituted carbapenems
-
Carbapenem antibiotic compounds of the general formula: STR1 wherein the moiety STR2 is a 4, 5 or 6 membered mono, di- or tri- substituted oxygen or sulfur containing ring; wherein Z is oxygen, sulfur, sulfoxide and sulfone, pharmaceutical compositions thereof useful for the treatment of bacterial infections, processes for preparing the compounds and new intermediates useful in the process.
- -
-
-
- Cephalosporin ester derivatives
-
A compound of the formula: STR1 wherein R1 is a hydrogen atom or a lower alkyl group; R2 is an unsubstituted or lower alkyl-substituted alicyclic alkyl group of 3 to 12 carbon atoms or a C3-6 alicyclic alkyl-substituted lower alkyl group or a pharmaceutically acceptable salt thereof, processes for preparing the same, a pharmaceutical composition thereof are provided. The compound has an improved absorbability and can be orally applied as antibiotics.
- -
-
-
- Antibacterial solid composition for oral administration
-
This invention relates to an antibacterial solid composition for oral administration which comprises a lipid soluble cephalosporin compound and a cyclodextrin. The said composition provides much increased in vivo absorbability of a non-ester form of the cephalosporin compound. This composition is useful for prevention and treatment of bacterial infections.
- -
-
-
- Anti-inflammatory 2-methyl-2H-1,2-benzo-(or -thieno-)thiazine-3-carboxamide 1,1-dioxide derivatives, compositions, and method of use therefor
-
Certain enol ether derivatives of oxicams (1,1-dioxides of N-heteroaryl-4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxamides and N-heteroaryl-4-hydroxy-2-methyl-2H-thieno[2,3-e]-1,2-thiazine-3-carboxamides) are useful as prodrugs of these antiinflammatory compounds.
- -
-
-
